Hoth Therapeutics To Present HT-001 And HT-KIT Oncology Programs At BIO-Europe 2025

Presentation to highlight advancements in Hoth's clinical pipeline, including

HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program

targeting KIT-driven tumors

NEW YORK, Oct. 7, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for dermatological, oncology, and Alzheimer's, today announced that Chief Executive Officer Robb Knie will be presenting at the upcoming BIO-Europe 2025 Conference, taking place November 3–5, 2025, in Vienna, Austria.

At the conference, Mr. Knie will highlight the Company's two leading development programs:

• HT-001 – a topical therapeutic designed to reduce rash and skin toxicity associated with cancer therapies, including EGFR inhibitors and radiotherapy.
   
• HT-KIT – a precision oncology program targeting cancers driven by dysregulated KIT signaling.